Rapport Therapeutics Inc Stock Price, News & Analysis

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on neurological and psychiatric disorder treatments, has announced a proposed public offering of $250.0 million of common stock. The company will grant underwriters a 30-day option to purchase up to an additional $37.5 million of shares.

The offering will be managed by joint book-runners Goldman Sachs, Jefferies, TD Cowen, and Stifel. The securities will be offered through an effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market conditions, with no guarantee of final terms or completion.

Rapport Therapeutics (NASDAQ: RAPP) announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures. The trial met its primary endpoint with 85.2% of patients achieving ≥30% reduction in long episodes from baseline (p<0.0001). Notably, patients demonstrated a 77.8% median reduction in clinical seizure frequency (p=0.01), with 24% achieving complete seizure freedom during the 8-week treatment period.

The drug was generally well-tolerated, with mostly mild adverse events and no serious adverse events reported. Based on these promising results, Rapport plans to advance RAP-219 into two Phase 3 pivotal trials in Q3 2026, following an FDA end-of-Phase 2 meeting in Q4 2025. The company is also developing a long-acting injectable formulation to improve patient adherence.

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing precision medicines for neurological and psychiatric disorders, has scheduled a conference call and webcast for September 8, 2025, at 8:00 am ET. The company will present topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

Investors can access the call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations using conference ID 4762775. A replay will be available on the company's website for 90 days after the call.

Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Dr. Raymond Sanchez to its Board of Directors effective August 12, 2025.

Dr. Sanchez brings over 20 years of strategic experience in life sciences and currently serves as Senior Advisor at Bain Capital Life Sciences. His extensive background includes roles as Chief Medical Officer at Cerevel Therapeutics and senior positions at Otsuka Pharmaceutical. The appointment comes as Alto prepares to initiate its potentially pivotal Phase 2b trial of ALTO-207.

A psychiatrist by training and former Chief Resident at Yale School of Medicine, Dr. Sanchez's expertise in CNS drug development aligns with Alto's mission to revolutionize neuropsychiatric treatment through precision medicine approaches.

Rapport Therapeutics (NASDAQ:RAPP) reported Q2 2025 financial results and provided key business updates. The company's lead program RAP-219 Phase 2a trial for drug-resistant focal onset seizures is fully enrolled with topline results expected in September 2025. Additionally, a Phase 2 trial of RAP-219 in bipolar mania has been initiated.

Financial highlights include a net loss of $26.7 million in Q2 2025, compared to $18.1 million in the prior year. R&D expenses increased to $22.7 million, up from $15.7 million. The company maintains a strong cash position of $260.4 million, expected to fund operations through 2026.

Clinical progress includes positive Phase 1 safety data across 100 healthy volunteers, with no serious adverse events reported. The company is also finalizing plans for a Phase 2a trial in diabetic peripheral neuropathic pain (DPNP).

Rapport Therapeutics (NASDAQ: RAPP) hosted its inaugural Investor and Analyst Day, announcing full enrollment in their Phase 2a trial of RAP-219 for refractory focal epilepsy, with topline results expected in September 2025. The trial includes 14 patients with median age 37 years and median seizure frequency of 10 per 28 days. The company reported consolidated Phase 1 safety data showing favorable tolerability across 100 healthy volunteers, with only Grade 1 or 2 adverse events. Key upcoming catalysts include a Phase 2a trial initiation in bipolar mania (Q3 2025) and updates on their diabetic peripheral neuropathic pain program (2H 2025). With $285.4 million in cash as of March 31, 2025, Rapport has runway through end of 2026.

Rapport Therapeutics (NASDAQ: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in two major healthcare investor conferences in June 2025.

The company will participate in fireside chats at the Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 10:30 a.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 10:00 a.m. ET. Both presentations will be accessible via webcast on the company's investor relations website.

Rapport Therapeutics (NASDAQ: RAPP) has announced its first-ever Investor and Analyst Day, scheduled for June 2, 2025, in New York City. The event, to be held at Nasdaq MarketSite from 3:00 to 5:00 p.m. ET, will feature presentations from senior management focusing on the company's clinical programs, particularly the RAP-219 Phase 2a trial in refractory focal epilepsy.

A highlight of the event will be a fireside chat with Dr. Jacqueline A. French, a renowned epilepsy researcher from NYU Langone's Comprehensive Epilepsy Center and principal investigator of the RAP-219 trial. The event will be accessible via live and archived webcasts through the company's investor relations website.

Rapport Therapeutics (NASDAQ: RAPP) reported Q1 2025 financial results and provided key business updates. The company's lead program RAP-219 is progressing with two significant Phase 2a trials: one for refractory focal epilepsy with topline results expected in Q3 2025, and another for bipolar mania starting in Q3 2025. The company reported favorable tolerability across four Phase 1 trials, with PET data showing selective targeting in epilepsy-associated brain regions.

Financial highlights include a Q1 2025 net loss of $24.1 million, with R&D expenses of $19.6 million and G&A expenses of $7.5 million. The company maintains a strong financial position with $285.4 million in cash and investments, expected to fund operations through 2026. Recent appointments include Dr. Jeffrey Sevigny as Chief Medical Officer, and the company plans to host its inaugural Investor and Analyst Day on June 2, 2025.